MARKET

PRAH

PRAH

PRA Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

99.99
-2.88
-2.80%
After Hours: 99.99 0 0.00% 16:33 09/21 EDT
OPEN
100.75
PREV CLOSE
102.87
HIGH
100.99
LOW
97.88
VOLUME
291.29K
TURNOVER
--
52 WEEK HIGH
113.32
52 WEEK LOW
58.67
MARKET CAP
6.40B
P/E (TTM)
30.61
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
PRA Health Sciences: A Solid Investment Case But Watch Out For Signs Of Inertia
I last covered PRA in May 2019 - the stock is up 14% since then, which was at the top end of my forecast at the time.Market selloffs aside, PRA's share price has hovered between $100-$110 mark for nearly 2 years - tough operating conditions due to the pandemic may be holding it back.PRA has dealt reasonably well with the crisis and are forecasting ~$3.1bn of revenues in FY20 as the midpoint of expectations - a slight increase on FY19.Momentum from 2 good quarters could see the share price break out above $115 and get close to my calculated fair value price of $127.Management and the company pass most of the investment tests but need to go above and beyond, in my view to make the company a "strong buy". I am mildly bullish.
Seekingalpha · 13h ago
PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens
PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.
Zacks · 14h ago
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials
The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trialsRALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc
GlobeNewswire · 3d ago
PRA Health Sciences, Deep Lens Announce Strategic Relationship To Accelerate Patient Recruitment For Precision Cancer Trials
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences,
Benzinga · 3d ago
PRA Health Sciences Announces Appointment of New Director
RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020. “We are delighted that Glen will be joining our Board of Directors.  With his widespread
GlobeNewswire · 6d ago
Hedge Funds Dipping Their Toes Back Into PRA Health Sciences Inc (PRAH)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an
Insider Monkey · 09/14 20:14
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Zacks · 09/09 11:00
Shareholders Are Thrilled That The PRA Health Sciences (NASDAQ:PRAH) Share Price Increased 129%
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Simply Wall St. · 09/08 19:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAH stock price target is 113.62 with a high estimate of 130.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 485
Institutional Holdings: 66.00M
% Owned: 103.18%
Shares Outstanding: 63.96M
TypeInstitutionsShares
Increased
101
4.17M
New
83
-319.30K
Decreased
121
4.76M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/President/Chief Executive Officer/Director
Colin Shannon
Chief Financial Officer/Executive Vice President
Michael Bonello
Executive Vice President/Chief Administrative Officer/General Counsel
Christopher Gaenzle
Lead Director/Independent Director
James Momtazee
Independent Director
Jeffrey Barber
Independent Director
Alexander Dickinson
Independent Director
Linda Grais
Independent Director
Glen Stettin
Independent Director
Matthew Young
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average PRAH stock price target is 113.62 with a high estimate of 130.00 and a low estimate of 100.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRAH
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of PRA Health Sciences Inc stock information, including NASDAQ:PRAH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAH stock methods without spending real money on the virtual paper trading platform.